CClinicalTrials.gg
Status unknownNCT01005992Updated Nov 1, 2009

Fractional Photothermolysis for the Treatment of Burn Scars

A Phase 1 interventional study of Fractional laser treatment and Standard scar management in Scar, sponsored by Clinica las Condes, Chile. Status unknown at 1 site in Chile. Open to participants aged 6 Years to 16 Years. Per ClinicalTrials.gov, last updated 2009-11-01.

Sponsored by Clinica las Condes, Chile · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Oct 2009), so the status shown — last known as Not yet recruiting — may be out of date.
Phase
Phase 1
Study type
Interventional
Enrollment
10
Allocation
Non-randomized
Ages
6 Years to 16 Years
Sex
All
01

Study summary

The aim of our study is to determine the effect of fractional photothermolysis laser in the treatment of burn scars.

Read the detailed description

One of the main problems in the management of burned patients is the treatment of post-burn scarring. Frequently this scars cover large areas, tend to retract, present pigmentary changes and are disfiguring, producing significant life quality impairment.

Unfortunately, there are very few therapeutic options for treating these scars, which can be secondary to reconstructive surgery or after spontaneous healing. In the last decades most reports in scar treatment have included, pressure garments, chemical peeling, dermabrasion, ablative and non-ablative laser therapy and surgery with varying degrees of success. There is only one report treating burn scars with fractional laser, with good results.

The aim of our study is to determine the effect of of a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc.) in the treatment of burn scars.

02

Conditions studied

  • Scar

Browse trials for

Keywords

  • Scars secondary to injuries to tissues caused by contact with physical (heat, electricity) o chemical agent.
03

In context

Cicatrix

306 studies on the registry are indexed under Cicatrix; 50 are open to participants now.

This study's planned enrollment of 10 is below the median of 39 across 250 interventional studies indexed under Cicatrix.

Browse Cicatrix studies →

Lead sponsor

Clinica las Condes, Chile is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Burn scars should be located on the anterior thorax or abdomen with at least 4 months of evolution.
  • The scar should be slightly elevated, with erythema and with no signs of keloid formation.
  • Maximum scar dimension: 0.2 - 1% body surface area.
  • Acceptance of informed consent for laser treatment.

Exclusion criteria

Exclusion Criteria:

  • Previous non-surgical treatment (i.e. dermabrasion, laser, peelings, bleaching agent. etc).
  • Previous surgical treatment (i.e. graft)
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Laser treated scar

    The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.

    Procedure: Fractional laser treatment

  • Active comparator
    Standard scar management

    The standard scar management arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.

    Procedure: Standard scar management

Interventions

  • ProcedureFractional laser treatment

    A complete treatment will consist in four laser sessions with a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc at 1-month intervals. Treatment will be delivered with a 15-mm tip and concomitant air-cooling system (Zimmer MedizinSystems, Irvine, CA). Fluence and treatment level will be registered on every session and will be adjusted according to patient tolerance.

  • ProcedureStandard scar management

    The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.

06

What researchers measure

Primary outcomes

  1. Evidence of improvement in color and texture of burn scars, using digital colorimeter and digital photography.

    Time frame: 5 months

  2. Adverse effects: pain, erythema, edema, hypopigmentation, hyperpigmentation, hypertrophic scar and keloid formation

    Time frame: 5 months

Secondary outcomes

  1. Change in surface area and perimeter of burn scar

    Time frame: 5 months

  2. Tissue pliability, elevation and flexibility with a digital piedemeter

    Time frame: 5 months

  3. Change in collagen fiber organization and blood vessel density with a reflectance laser confocal microscope.

    Time frame: 5 months

07

Study locations

1 site
  • Clinica Las Condes
    Santiago, RM, Chile
    • Rodrigo J Schwartz, MD · Contact · 56-2-6108661
    • Fresia Solias · Contact · investigacion@coaniquem.cl
    • Rodrigo J Schwartz, MD · Principal investigator
    • Fresia Solis · Sub investigator
    • Gonzalo Eguiguren, MD · Sub investigator
    • Jorge Rojas, MD · Sub investigator
    • pedro lobos, MD · Sub investigator
    • Patricia Apt, MD · Sub investigator
08

References and documents

Publications

  • Chrastil B, Glaich AS, Goldberg LH, Friedman PM. Second-generation 1,550-nm fractional photothermolysis for the treatment of acne scars. Dermatol Surg. 2008 Oct;34(10):1327-32. doi: 10.1111/j.1524-4725.2008.34284.x. PubMed 19040687 ↗
  • Glaich AS, Rahman Z, Goldberg LH, Friedman PM. Fractional resurfacing for the treatment of hypopigmented scars: a pilot study. Dermatol Surg. 2007 Mar;33(3):289-94; discussion 293-4. doi: 10.1111/j.1524-4725.2007.33058.x. PubMed 17338685 ↗
  • Haedersdal M. Fractional ablative CO(2) laser resurfacing improves a thermal burn scar. J Eur Acad Dermatol Venereol. 2009 Nov;23(11):1340-1. doi: 10.1111/j.1468-3083.2009.03215.x. Epub 2009 Mar 4. No abstract available. PubMed 19309424 ↗
  • Haedersdal M, Moreau KE, Beyer DM, Nymann P, Alsbjorn B. Fractional nonablative 1540 nm laser resurfacing for thermal burn scars: a randomized controlled trial. Lasers Surg Med. 2009 Mar;41(3):189-95. doi: 10.1002/lsm.20756. PubMed 19291747 ↗
  • Waibel J, Beer K. Fractional laser resurfacing for thermal burns. J Drugs Dermatol. 2008 Jan;7(1):59-61. PubMed 18246699 ↗
  • Waibel J, Beer K. Ablative fractional laser resurfacing for the treatment of a third-degree burn. J Drugs Dermatol. 2009 Mar;8(3):294-7. PubMed 19271380 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 1, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01005992
Lead sponsor
Clinica las Condes, Chile
Collaborators
Corporacion de ayuda al niño quemado (COANIQUEM), Solta Medical
First posted
Nov 1, 2009
Start date
Nov 2009
Primary completion
Apr 2010 (estimated)
Last update
Nov 1, 2009

Study contacts

Rodrigo Schwartz, MD
Contact
schwartz.rodrigo@gmail.com
56-2-6108661
Rodrigo J Schwartz, MD
principal investigator · Clinica Las Condes

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Oct 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion